natgillin/translations-raw huggingface dataset:
Sildenafil is also used for the treatment of erectile dysfunction.
Sildenafil se primjenjuje i za liječenje erektilne disfunkcije.
25-O-desacetyl-rifabutin: AUC: ↑525% Cmax: ↑384% Cmin: ↑394%
25-O-dezacetil-rifabutin: AUC: ↑525% Cmax: ↑384% Cmin: ↑394%
The increased incidence of benign hepatic adenomas in female mice was likely secondary to cytotoxic liver changes manifested by single-cell necrosis and is considered to have no relevance for humans at intended therapeutic exposures.
Povećana incidencija benignih adenoma jetre u ženki miša vjerojatno je bila posljedica citotoksičnih promjena u jetri koje su se očitovale nekrozom pojedinačnih stanica, ali smatra se da to nije značajno za ljude pri planiranoj terapijskoj izloženosti.
HORMONAL CONTRACEPTIVES Progestin/estrogen
Progestin/estrogen
Calcium channel blockers
Blokatori kalcijevih kanala
High density polyethylene (HDPE) bottle with a child-resistant polypropylene closure.
Boca od polietilena visoke gustoće (HDPE) s polipropilenskim sigurnosnim zatvaračem za djecu.
If you feel dizzy or lightheaded, please contact your doctor immediately.
Ako osjetite omaglicu ili ošamućenost, odmah se obratite svom liječniku.
Cobicistat AUC ↔ Cobicistat Cmax ↔ Cobicistat Cmin ↑232%
Kobicistat AUC ↔ Kobicistat Cmax ↔ Kobicistat Cmin ↑232%
The following statements reflect the preclinical safety results of the individual active substances of EVOTAZ.
Sljedeći odlomci opisuju rezultate nekliničkih ispitivanja sigurnosti primjene pojedinačnih djelatnih tvari lijeka EVOTAZ.
Cobicistat is 97-98% bound to human plasma proteins and the mean plasma to blood drug concentration ratio was 2.
Vezanje kobicistata za proteine u plazmi ljudi iznosi 97-98%, a srednji omjer koncentracije lijeka u plazmi i krvi iznosio je 2.
The recommendations given for concomitant use of atazanavir and other medicinal products may, therefore, differ depending on whether atazanavir is boosted with ritonavir or cobicistat.
Preporuke za istodobnu primjenu atazanavira i drugih lijekova mogu se stoga razlikovati ovisno o tome pojačava li se atazanavir ritonavirom ili kobicistatom.
ANTIDEPRESSANTS Other antidepressants:
Drugi antidepresivi:
In pregnant rabbits, gross lesions of the stomach and intestines were observed in dead or moribund does at maternal doses 2 and 4 times the highest dose administered in the definitive embryo-development study.
U skotnih ženki kunića opažene su velike lezije na želucu i crijevima u mrtvih ženki kunića ili ženki kunića na umoru pri dozama koje su bile 2 odnosno 4 puta veće od najviše doze primijenjene u zaključnom ispitivanju embrionalnog razvoja.
EVOTAZ should not be used in combination with another antiretroviral that requires pharmacokinetic enhancement (i.e., another protease inhibitor or elvitegravir) since dosing recommendations for such combinations have not been established and may result in decreased plasma concentrations of atazanavir and/or the other antiretroviral leading to loss of therapeutic effect and development of resistance.
EVOTAZ se ne smije primjenjivati u kombinaciji s nekim drugim antiretrovirotikom koji zahtijeva primjenu farmakokinetičkog pojačivača (tj. nekim drugim inhibitorom proteaze ili elvitegravirom) jer nisu utvrđene preporuke za doziranje kod takvih kombinacija i može doći do smanjenja plazmatskih koncentracija atazanavira i/ili drugog antiretrovirotika, što za posljedicu može imati gubitak terapijskog učinka i razvoj rezistencije.
Atazanavir increases tenofovir concentrations.
Atazanavir povisuje koncentracije tenofovira.
Some examples include, but are not limited to, itraconazole, ketoconazole and voriconazole (see Table 1).
Neki primjeri uključuju, između ostalog na itrakonazol, ketokonazol i vorikonazol (vidjeti Tablicu 1).
Cobicistat has not been studied in patients with severe hepatic impairment and is not recommended in these patients.
Kobicistat nije ispitivan u bolesnika s teškim oštećenjem jetrene funkcije i stoga se njegova primjena u tih bolesnika ne preporučuje.
If you notice any symptoms of infection, please inform your doctor immediately.
Ako primijetite bilo koji simptom infekcije, odmah o tome obavijestite svog liječnika.
In in vivo studies in rats, atazanavir did not induce micronuclei in bone marrow, DNA damage in duodenum (comet assay), or unscheduled DNA repair in liver at plasma and tissue concentrations exceeding those that were clastogenic in vitro.
U in vivo ispitivanjima u štakora, atazanavir nije inducirao nastanak mikronukleusa u koštanoj srži, oštećenje DNK u duodenumu (kometni test) ni neplaniran popravak DNK u jetri pri koncentracijama u plazmi i tkivu većima od onih koje su bile klastogene in vitro.
Patients should be warned about these possible side effects when using PDE5 inhibitors for erectile dysfunction with EVOTAZ (see section 4.4).
Bolesnike treba upozoriti na ove moguće nuspojave kad se inhibitori PDE5 za liječenje erektilne disfunkcije primjenjuju istodobno s lijekom EVOTAZ (vidjeti dio 4.4).
The most frequently reported laboratory abnormality in paediatric patients receiving atazanavir was elevation of total bilirubin (≥ 2.6 times ULN, Grade 3-4) which occurred in 45% of patients.
Najčešće prijavljeno odstupanje u laboratorijskim nalazima u pedijatrijskih bolesnika liječenih atazanavirom bilo je povišenje razine ukupnog bilirubina (≥ 2,6 puta GGN, 3.-4. stupanj), koje se javilo u 45% bolesnika.
If you notice any of these symptoms please inform your doctor.
Ako primijetite neki od tih simptoma, obavijestite o tome svog liječnika.
The most frequently reported laboratory abnormality in patients receiving regimens containing atazanavir and one or more NRTIs was elevated total bilirubin reported predominantly as elevated indirect [unconjugated] bilirubin (87% Grade 1, 2, 3, or 4).
Najčešće prijavljena odstupanja u laboratorijskim nalazima u bolesnika liječenih režimima koji su sadržavali atazanavir i jedan ili više NRTI-jeva bile su povišene razine ukupnog bilirubina prijavljene prvenstveno kao povišene razine indirektnog [nekonjugiranog] bilirubina (87% 1., 2., 3. ili 4. stupnja).
Atazanavir concentrations were greatly decreased when co-administered with didanosine (buffered tablets) and stavudine.
Koncentracije atazanavira jako su se smanjile kod istodobne primjene s didanozinom (puferirane tablete) i stavudinom.
Atazanavir has been studied in adult patients with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily.
Atazanavir se ispitivao u odraslih bolesnika s teškim oštećenjem funkcije bubrega (n=20), uključujući one na hemodijalizi, uz primjenu višestrukih doza od 400 mg jedanput na dan.
14-OH clarithromycin 14-OH clarithromycin AUC ↓70%
14-OH klaritromicin 14-OH klaritromicin AUC ↓70%
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of cobicistat has not been studied.
Učinak teškog oštećenja jetrene funkcije (Child-Pugh stadij C) na farmakokinetiku kobicistata nije ispitivan.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions (see section 4.8).
Bolesnici s kroničnim hepatitisom B ili C liječeni kombiniranom antiretrovirusnom terapijom imaju povećan rizik od teških i potencijalno smrtonosnih jetrenih nuspojava (vidjeti dio 4.8).
No subject developed the tenofovir-associated resistance substitution K65R or K70E or any primary resistance substitution associated with protease inhibitors.
Ni u jednog se ispitanika nije razvila supstitucija K65R ili K70E povezana s rezistencijom na tenofovir niti bilo koja primarna supstitucija povezana s rezistencijom na inhibitore proteaze.
Corticosteroids primarily metabolised by CYP3A (including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone).
Kortikosteroidi koji se prvenstveno metaboliziraju puetm CYP3A (uključujući betametazon, budezonid, flutikazon, mometazon, prednizon, traimcinolon).
Recommended dosage of colchicine when administered with EVOTAZ in patients without renal or hepatic impairment: a dose reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with EVOTAZ is required.
Preporučeno doziranje kolhicina pri istodobnoj primjeni s lijekom EVOTAZ u bolesnika bez oštećenja bubrežne ili jetrene funkcije: preporučuje se smanjenje doze kolhicina ili privremen prekid liječenja kolhicinom u bolesnika s normalnom bubrežnom i jetrenom funkcijom ako je potrebno liječenje lijekom EVOTAZ.
ANTINEOPLASTICS AND IMMUNOSUPRESSANTS
ANTINEOPLASTICI I IMUNOSUPRESIVI
Cobicistat is not expected to induce CYP3A4 or P-gp.
Ne očekuje se da će kobicistat inducirati CYP3A4 ili P-gp.
In long-term carcinogenicity studies of atazanavir in mice and rats, an increased incidence of benign hepatic adenomas was seen in female mice only.
U dugotrajnim ispitivanjima kancerogenosti atazanavira u miševa i štakora opažena je povećana incidencija benignih adenoma jetre, ali samo u ženki miša.
Atazanavir with cobicistat and emtricitabine and tenofovir DF fixed-dose combination was non-inferior in achieving HIV-1 RNA <50 copies/ml when compared to atazanavir with ritonavir and emtricitabine and tenofovir DF fixed-dose combination.
Atazanavir s kobicistatom i kombinacijom fiksnih doza emtricitabina i tenofovira DF pokazao se neinferiornim u postizanju razine HIV-1 RNK od < 50 kopija/ml u usporedbi s atazanavirom s ritonavirom i kombinacijom fiksnih doza emtricitabina i tenofovira DF.
One EVOTAZ tablet is bioequivalent to one atazanavir capsule (300 mg) plus one cobicistat tablet (150 mg) following single oral dose administration with a light meal in healthy subjects (n=62).
Jedna EVOTAZ tableta bioekvivalentna je jednoj kapsuli atazanavira (300 mg) plus jednoj tableti kobicistata (150 mg) primijenjenima peroralno u jednokratnoj dozi uz lagan obrok u zdravih ispitanika (n=62).
In rats, ossification changes in the spinal column and sternebra of foetuses occurred at a dose that produced significant maternal toxicity.
Osifikacijske promjene na kralježnici i sternebri fetusa štakora pojavile su se pri dozi koja je uzrokovala značajnu toksičnost za majku.
The mechanism of interaction between atazanavir/ritonavir and sofosbuvir/velpatasvir/voxilaprevir is inhibition of OATP1B, Pgp, and CYP3A.
Mehanizam interakcije između atazanavira/ritonavira i sofosbuvira/velpatasvira/voksilaprevira je inhibicija OATP1B, Pgp-a i CYP3A.
Higher plasma concentrations of coadministered medicinal products can result in increased or prolonged therapeutic effects or adverse reactions.
Povišene plazmatske koncentracije istodobno primijenjenih lijekova mogu za posljedicu imati pojačane ili produljene terapijske učinke ili nuspojave.
Following oral administration of [14C]cobicistat, 99% of circulating radioactivity in plasma was unchanged cobicistat.
Nakon peroralne primjene [14C]kobicistata, 99% cirkulirajuće radioaktivnosti u plazmi činio je kobicistat u neizmijenjenom obliku.
Treatment difference -2.2% (95% CI = -7.4%, 3.0%) -2.1% (95% CI = -8.7%, 4.5%) Virologic failurec
-2,2% (95% CI = -7,4%; 3,0%) -2,1% (95% CI = -8,7%; 4,5%)
They work by reducing the amount of HIV in your body and this in turn, strengthens your immune system.
Djeluju tako što smanjuju količinu HIV-a u tijelu, što jača imunosni sustav.
Co-administration with EVOTAZ can increase plasma concentrations of medicinal products that are metabolised by CYP2D6 (see sections 4.3 and 4.5).
Istodobna primjena s lijekom EVOTAZ može povisiti plazmatske koncentracije lijekova koje metabolizira CYP2D6 (vidjeti dijelove 4.3 i 4.5).
Co-administration warrants clinical monitoring for sedation and cognitive effects.
Istodobna primjena zahtijeva kliničko praćenje zbog moguće sedacije i kognitivnih učinaka.
Clinical monitoring is recommended when dabigatran is co-administered with P-gp inhibitors.
Preporučuje se kliničko praćenje kada se dabigatran primjenjuje istodobno s inhibitorima P-gp-a.
When co-administering tenofovir alafenamide/emtricitabine and EVOTAZ, the recommended dose of tenofovir alafenamide/emtricitabine is 10/200 mg once daily.
Pri istodobnoj primjeni tenofoviralafenamida/emtricitabina i lijeka EVOTAZ, preporučena doza tenofoviralafenamida/emtricitabina je 10/200 mg jedanput na dan.
EVOTAZ is to be taken orally with food (see section 5.2).
EVOTAZ se uzima peroralno, s hranom (vidjeti dio 5.2).
There are currently inadequate data to determine whether co-administration of tenofovir disoproxil and cobicistat is associated with a greater risk of renal adverse reactions compared with regimens that include tenofovir disoproxil without cobicistat.
Trenutno nema odgovarajućih podataka na temelju kojih bi se utvrdilo je li istodobna primjena tenofovirdizoproksila i kobicistata povezana s povećanim rizikom od bubrežnih nuspojava u usporedbi s režimima koji uključuju tenofovirdizoproksilbez kobicistata.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.
Ako u tih bolesnika postoje dokazi pogoršanja bolesti jetre, mora se razmotriti privremen ili trajan prekid liječenja.
In repeat-dose toxicity studies, conducted in mice, rats, and dogs, atazanavir-related findings were generally confined to the liver and included generally minimal to mild increases in serum bilirubin and liver enzymes, hepatocellular vacuolation and hypertrophy, and, in female mice only, hepatic single-cell necrosis.
U ispitivanjima toksičnosti ponovljenih doza provedenih u miševa, štakora i pasa, nalazi povezani s atazanavirom općenito su bili ograničeni na jetru i obično su uključivali minimalna do blaga povišenja serumskog bilirubina i jetrenih enzima, hepatocelularnu vakuolizaciju i hipertrofiju te, samo u ženki miša, nekrozu pojedinačnih jetrenih stanica.
Given that cobicistat has been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co-administered with EVOTAZ.
Budući da se pokazalo da kobicistat ne utječe značajno na koncentracije metadona, ne očekuje se interakcija pri istodobnoj primjeni metadona s lijekom EVOTAZ.
No significant effect on atazanavir concentrations was observed when administered with enteric-coated didanosine, but administration with food decreased didanosine concentrations.
Nije opažen značajan učinak na koncentracije atazanavira kod primjene sa želučanootpornim kapsulama didanozina, ali je primjena s hranom snizila koncentracije didanozina.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici i kutiji iza 'Rok valjanosti'.
Each bottle contains 30 film-coated tablets and a silica gel dessicant.
Jedna boca sadrži 30 filmom obloženih tableta i silikagel kao sredstvo za sušenje.
Concentrations of ethinyl estradiol and norethindrone are increased when a combined oral contraceptive containing those agents is co-administered with atazanavir.
Koncentracije etinilestradiola i noretindrona se povisuju kada se kombinirani oralni kontraceptiv koji sadrži te tvari primjenjuje istodobno s atazanavirom.
Atazanavir is a weak to moderate inhibitor of CYP2C8.
Atazanavir je slab do umjeren inhibitor CYP2C8.
In the group receiving atazanavir 300 mg co-administered with ritonavir 100 mg, evaluable genotypic data was available for all 19 virologic failures (5%, 19/348).
U skupini koja je primala atazanavir u dozi od 300 mg istodobno s ritonavirom u dozi od 100 mg, ocjenjivi genotipski podaci bili su dostupni za svih 19 slučajeva virološkog neuspjeha (5%, 19/348).
ANTIDIABETICS Metformin
ANTIDIJABETICI Metformin
It is important to tell your doctor if you are taking: Corticosteroids including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone.
Važno je da obavijestite svog liječnika ako uzimate: Kortikosteroide koji uključuju betametazon, budezonid, flutikazon, mometazon, prednizon, triamcinolon.
Cobicistat exposures are non-linear and greater than dose-proportional over the range of 50 mg to 400 mg, consistent with a mechanism-based CYP3A inhibitor.
Izloženost kobicistatu je nelinearna i veća od one proporcionalne dozi u rasponu doza od 50 mg do 400 mg, što odgovara inhibitoru enzima CYP3A temeljeno na mehanizmu.
The activity of cobicistat as a pharmacokinetic enhancer to atazanavir has been demonstrated in pharmacokinetic trials.
Aktivnost kobicistata kao farmakokinetičkog pojačivača atazanavira dokazana je u farmakokinetičkim ispitivanjima.
The potential for PR prolongation should be considered in cases of overdose (see section 4.9).
U slučajevima predoziranja treba uzeti u obzir mogućnost produljenja PR-intervala (vidjeti dio 4.9).
Atazanavir exhibits anti-HIV-1 (including all clades tested) and anti-HIV-2 activity in cell culture.
Atazanavir u staničnoj kulturi ima anti-HIV-1 (uključujući sve ispitane sojeve) i anti-HIV-2 aktivnost.
NEUROLEPTICS Perphenazine Risperidone Thioridazine
NEUROLEPTICI Perfenazin Risperidon Tioridazin
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nenukleozidni inhibitori reverzne transkriptaze (NNRTI))
The recommendations shown in Table 1 are based on either drug interaction trials of unboosted atazanavir, atazanavir boosted with ritonavir, cobicistat or predicted interactions due to the expected magnitude of the interaction and potential for serious adverse reactions or loss of therapeutic effect of EVOTAZ.
Preporuke prikazane u Tablici 1 temelje se ili na ispitivanjima interakcija nepojačanog atazanavira, atazanavira pojačanog ritonavirom i atazanavira pojačanog kobicistatom ili na interakcijama koje se predviđaju na temelju očekivane jačine interakcije i mogućnosti nastupa ozbiljnih nuspojava ili gubitka terapijskog učinka lijeka EVOTAZ.
Concentrations of ketoconazole, itraconazole, and/or cobicistat may be increased with co-administration of ketoconazole or itraconazole with EVOTAZ.
Koncentracije ketokonazola, itrakonazola i/ili kobicistata mogu porasti kod istodobne primjene ketokonazola ili itrakonazola i lijeka EVOTAZ.
Other marked clinical laboratory abnormalities (Grade 3 or 4) reported in ≥ 2% of patients receiving regimens containing atazanavir and one or more NRTIs included: elevated creatine kinase (7%), elevated alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT) (5%), low neutrophils (5%), elevated aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) (3%), and elevated lipase (3%).
Ostala značajna klinička odstupanja u laboratorijskim nalazima (3. ili 4. stupnja) prijavljena u ≥ 2% bolesnika koji su primali režime s atazanavirom i jednim ili više NRTI-ja uključivali su: povišenu razinu kreatin kinaze (7%), povišenu alanin aminotransferazu/serumsku glutamat-piruvat transaminazu (ALT/SGPT) (5%), nizak broj neutrofila (5%), povišenu aspartat aminotransferazu/serumsku glutamat-oksaloacetat transaminazu (AST/SGOT) (3%) i povišenu razinu lipaze (3%).
Plasma levels of cobicistat and consequently of atazanavir may decrease significantly during pregnancy.
Vrijednosti kobicistata i posljedično atazanavira u plazmi mogu značajno pasti tijekom trudnoće.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART.
Prijavljeni su slučajevi osteonekroze, osobito u bolesnika s opće poznatim čimbenicima rizika, uznapredovalom HIV bolešću ili dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji.
When co-administering with EVOTAZ, titrate the digoxin dose and monitor digoxin concentrations.
Kod istodobne primjene s lijekom EVOTAZ, potrebno je titrirati dozu digoksina i kontrolirati njegove koncentracije.
When co-administering maraviroc and EVOTAZ, patients should receive maraviroc 150 mg twice daily.
Kada se maravirok primjenjuje istodobno s lijekom EVOTAZ, bolesnici trebaju primati 150 mg maraviroka dvaput na dan.
There is a risk of loss of therapeutic effect and development of resistance to atazanavir (see section 4.3).
Postoji rizik od gubitka terapijskog učinka i razvoja rezistencije na atazanavir (vidjeti dio 4.3).
Use of other antiplatelets not affected by CYP inhibition or induction (e.g. prasugrel) is recommended (see section 4.3).
Preporučuje se primjena drugih antitrombotika na koje ne utječu inhibicija ili indukcija CYP enzima (npr. prasugrel) (vidjeti dio 4.3).
Since atazanavir and cobicistat are extensively metabolised by the liver and highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicinal product.
Budući da se atazanavir i kobicistat opsežno metaboliziraju u jetri i u visokoj mjeri vežu za proteine u plazmi, nije vjerojatno da će dijaliza biti korisna za uklanjanje ovog lijeka u znatnijoj mjeri.
Cmax: ↑41% Cmin: not determined
AUC: ↔ Cmax: ↑41% Cmin: nije određen
EVOTAZ should not be co-administered with triazolam or orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of EVOTAZ and parenteral midazolam.
EVOTAZ se ne smije primjenjivati istodobno s triazolamom ili peroralno primijenjenim midazolamom (vidjeti dio 4.3), dok je kod istodobne primjene lijeka EVOTAZ i parenteralnog midazolama potreban oprez.
ANTIPSYCHOTICS Pimozide
ANTIPSIHOTICI Pimozid
Amiodarone, dronedarone, quinidine and systemic lidocaine have a narrow therapeutic window and are contraindicated due to potential inhibition of CYP3A by EVOTAZ (see section 4.3).
Amiodaron, dronedaron, kinidin i sistemski lidokain imaju uzak terapijski raspon te je njihova primjena kontraindicirana zbog moguće inhibicije CYP3A koju uzrokuje EVOTAZ (vidjeti dio 4.3).
Pink, oval, biconvex, film-coated tablet of approximate dimensions of 19 mm x 10.4 mm, debossed with "3641" on one side and plain on the other side.
Ružičasta, ovalna, bikonveksna, filmom obložena tableta dimenzija približno 19 mm x 10,4 mm, s utisnutom oznakom "3641" na jednoj strani i bez oznake na drugoj strani.
Effect on atazanavir and ritonavir exposure has not been studied.
Učinak na izloženost atazanaviru i ritonvairu nije ispitivan.
For further details, consult the Summary of Product Characteristics for maraviroc.
Za više informacija pročitajte Sažetak opisa svojstava lijeka za maravirok.
Among the 21 subjects, 3 developed the emtricitabine-associated resistance substitution M184V.
Među tih 21 ispitanika, u njih 3 se razvila supstitucija M184V povezana s rezistencijom na emtricitabin.
Subjects with significant liver function test abnormalities generally had abnormal baseline transaminases (AST or ALT), underlying chronic or acute hepatitis B or C co-infection, concomitant hepatotoxic medications (e.g., isoniazid), or a medical history of alcoholism or alcohol abuse.
Ispitanici sa značajnim odstupanjima u nalazima testova jetrene funkcije u načelu su imali abnormalne početne razine transaminaza (AST-a ili ALT-a), podležeću kroničnu ili akutnu istodobnu infekciju hepatitisom B ili C, istodobno su uzimali hepatotoksične ljekove (npr. izoniazid) ili su u anamnezi imali alkoholizam ili prekomjerno uživanje alkohola.
The overall safety profile of EVOTAZ is based on available data from clinical trials conducted with atazanavir, atazanavir boosted with either cobicistat or ritonavir, and post-marketing data.
Ukupan profil sigurnosti lijeka EVOTAZ temelji se na dostupnim podacima iz kliničkih ispitivanja provedenih s atazanavirom i atazanavirom pojačanim kobicistatom ili ritonavirom te podacima prikupljenima nakon stavljanja lijeka u promet.
Following a single 400 mg dose of [14C]atazanavir, 79% and 13% of the total radioactivity was recovered in the faeces and urine, respectively.
Nakon jednokratne doze od 400 mg [14C]atazanavira, 79% ukupne radioaktivnosti pronađeno je u fecesu, a 13% u mokraći.
Concomitant administration of boceprevir and atazanavir/ritonavir resulted in reduced exposures to atazanavir and ritonavir.
Istodobna primjena boceprevira i atazanavira/ritonavira smanjila je izloženost atazanaviru i ritonaviru.
Itraconazole, like ketoconazole, is a potent inhibitor as well as a substrate of CYP3A4.
Kao i ketokonazol, itrakonazol je snažan inhibitor, ali i supstrat za CYP3A4.